PriceTargets.com logo

Sarepta Therapeutics - SRPT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $181.33
  • Forecasted Upside: 63.57%
  • Number of Analysts: 22
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 20 Buy Ratings
  • 1 Strong Buy Ratings
$110.86 As of 11/20/2024 01:00 AM ET
▲ +4.24 (3.98%)

This chart shows the closing price for SRPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sarepta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRPT

Analyst Price Target is $181.33
▲ +63.57% Upside Potential
This price target is based on 22 analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $181.33, with a high forecast of $230.00 and a low forecast of $109.00. The average price target represents a 63.57% upside from the last price of $110.86.

This chart shows the closing price for SRPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 22 contributing investment analysts is to buy stock in Sarepta Therapeutics. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 16 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 20 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 20 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024GuggenheimBoost TargetBuy ➝ Buy$148.00 ➝ $150.00
11/7/2024Robert W. BairdLower TargetOutperform ➝ Outperform$200.00 ➝ $193.00
11/7/2024Evercore ISILower TargetOutperform ➝ Outperform$179.00 ➝ $170.00
11/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$205.00 ➝ $205.00
11/7/2024Cantor FitzgeraldUpgradeNeutral ➝ Overweight$152.00 ➝ $167.00
10/21/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$182.00 ➝ $182.00
10/21/2024Jefferies Financial GroupInitiated CoverageBuy$165.00
10/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$205.00 ➝ $205.00
10/10/2024Raymond JamesReiterated RatingOutperform$150.00
10/4/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$181.00 ➝ $182.00
9/20/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$152.00 ➝ $152.00
9/19/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
9/17/2024UBS GroupBoost TargetBuy ➝ Buy$173.00 ➝ $188.00
9/6/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
8/30/2024William BlairUpgradeStrong-Buy
8/15/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
8/8/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$182.00 ➝ $181.00
8/8/2024CitigroupLower TargetNeutral ➝ Neutral$176.00 ➝ $160.00
8/8/2024Cantor FitzgeraldLower TargetNeutral ➝ Neutral$167.00 ➝ $152.00
8/8/2024Evercore ISIUpgradeIn-Line ➝ Outperform$185.00 ➝ $179.00
8/8/2024BarclaysLower TargetOverweight ➝ Overweight$226.00 ➝ $203.00
8/8/2024Piper SandlerLower TargetOverweight ➝ Overweight$205.00 ➝ $200.00
7/29/2024Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$182.00
7/1/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$205.00 ➝ $205.00
6/27/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$235.00 ➝ $235.00
6/26/2024CitigroupDowngradeBuy ➝ Neutral$172.00 ➝ $176.00
6/24/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$139.00 ➝ $185.00
6/24/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$165.00 ➝ $230.00
6/24/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$170.00 ➝ $200.00
6/21/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$157.00 ➝ $157.00
6/21/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$165.00 ➝ $165.00
6/21/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$128.00 ➝ $128.00
6/21/2024BarclaysBoost TargetOverweight ➝ Overweight$185.00 ➝ $226.00
6/21/2024Needham & Company LLCBoost TargetBuy ➝ Buy$166.00 ➝ $235.00
6/21/2024Bank of AmericaBoost TargetBuy ➝ Buy$166.00 ➝ $213.00
6/21/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$142.00 ➝ $182.00
6/21/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$170.00 ➝ $200.00
6/14/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$170.00 ➝ $170.00
5/31/2024Piper SandlerInitiated CoverageOverweight$157.00
5/28/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$157.00 ➝ $142.00
5/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$166.00
5/17/2024MizuhoBoost TargetBuy ➝ Buy$145.00 ➝ $179.00
5/14/2024OppenheimerUpgradeMarket Perform ➝ Outperform$180.00
5/3/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$177.00 ➝ $175.00
5/2/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$128.00
5/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$166.00
3/1/2024UBS GroupBoost TargetBuy ➝ Buy$164.00 ➝ $167.00
2/29/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$128.00
2/29/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$151.00 ➝ $157.00
2/29/2024WedbushReiterated RatingOutperform$224.00
2/29/2024CitigroupBoost TargetBuy ➝ Buy$160.00 ➝ $172.00
2/29/2024BarclaysBoost TargetOverweight ➝ Overweight$141.00 ➝ $185.00
2/29/2024Needham & Company LLCLower TargetBuy ➝ Buy$169.00 ➝ $166.00
2/20/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$108.00 ➝ $138.00
2/20/2024WedbushReiterated RatingOutperform ➝ Outperform$224.00
2/16/2024Needham & Company LLCBoost TargetBuy ➝ Buy$140.00 ➝ $169.00
2/14/2024MizuhoBoost TargetBuy ➝ Buy$130.00 ➝ $145.00
2/14/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$128.00
1/31/2024BMO Capital MarketsInitiated CoverageOutperform$170.00
1/29/2024WedbushReiterated RatingOutperform ➝ Outperform$224.00
1/29/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$140.00
1/25/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$155.00 ➝ $151.00
1/10/2024Needham & Company LLCBoost TargetBuy ➝ Buy$93.00 ➝ $140.00
1/9/2024WedbushReiterated RatingOutperform ➝ Outperform$224.00
12/13/2023CitigroupInitiated CoverageBuy$113.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$109.00
11/21/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$148.00
11/21/2023WedbushInitiated CoverageOutperform$224.00
11/2/2023BarclaysLower TargetOverweight ➝ Overweight$193.00 ➝ $141.00
10/31/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$211.00 ➝ $115.00
10/31/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$217.00 ➝ $148.00
10/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$166.00 ➝ $40.00
10/31/2023OppenheimerDowngradeOutperform ➝ Market Perform
10/31/2023Morgan StanleyLower TargetOverweight ➝ Overweight$183.00 ➝ $146.00
10/31/2023Needham & Company LLCLower TargetBuy ➝ Buy$185.00 ➝ $82.00
9/26/2023MizuhoReiterated RatingBuy ➝ Buy$160.00
8/3/2023Needham & Company LLCReiterated RatingBuy$185.00
8/3/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$183.00
8/3/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$221.00 ➝ $223.00
7/14/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$183.00
6/23/2023CitigroupLower Target$204.00 ➝ $161.00
6/23/2023JPMorgan Chase & Co.Lower Target$217.00 ➝ $213.00
6/23/2023Bank of AmericaBoost Target$176.00 ➝ $186.00
6/23/2023BarclaysBoost Target$170.00 ➝ $193.00
5/30/2023Evercore ISILower Target$173.00 ➝ $151.00
5/24/2023Credit Suisse GroupLower Target$151.00 ➝ $141.00
5/16/2023Royal Bank of CanadaBoost Target$197.00 ➝ $218.00
5/15/2023Bank of AmericaBoost Target$164.00 ➝ $176.00
5/15/2023UBS GroupBoost Target$160.00 ➝ $173.00
5/15/2023Credit Suisse GroupBoost Target$138.00 ➝ $151.00
5/3/2023Cantor FitzgeraldLower Target$165.00 ➝ $158.00
4/26/2023Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$185.00
4/14/2023MizuhoReiterated RatingBuy$160.00
4/12/2023Morgan StanleyLower Target$187.00 ➝ $183.00
4/4/2023CitigroupInitiated CoverageBuy ➝ Buy$179.00
3/22/2023TD CowenBoost TargetOutperform$125.00 ➝ $175.00
3/17/2023Royal Bank of CanadaLower TargetOutperform$226.00 ➝ $200.00
3/17/2023MizuhoReiterated RatingBuy$160.00
3/17/2023Cantor FitzgeraldLower Target$178.00 ➝ $165.00
3/17/2023Credit Suisse GroupLower TargetNeutral$144.00 ➝ $139.00
3/17/2023Needham & Company LLCLower TargetBuy$200.00 ➝ $160.00
3/9/2023OppenheimerLower TargetOutperform$180.00 ➝ $150.00
3/3/2023JPMorgan Chase & Co.Boost TargetOverweight$153.00 ➝ $206.00
3/1/2023Needham & Company LLCBoost TargetBuy$160.00 ➝ $200.00
3/1/2023The Goldman Sachs GroupBoost TargetBuy$171.00 ➝ $190.00
3/1/2023Royal Bank of CanadaBoost TargetOutperform$195.00 ➝ $226.00
3/1/2023OppenheimerBoost TargetOutperform$150.00 ➝ $180.00
3/1/2023Credit Suisse GroupBoost TargetNeutral$137.00 ➝ $144.00
3/1/2023Robert W. BairdBoost TargetOutperform$152.00 ➝ $202.00
3/1/2023BarclaysBoost Target$149.00 ➝ $170.00
3/1/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$141.00 ➝ $187.00
2/15/2023Credit Suisse GroupBoost TargetNeutral$114.00 ➝ $137.00
1/20/2023Leerink PartnersReiterated RatingOutperform$160.00
1/11/2023CowenBoost Target$114.00 ➝ $125.00
1/10/2023Needham & Company LLCBoost TargetBuy$158.00 ➝ $160.00
1/10/2023Credit Suisse GroupBoost TargetNeutral$101.00 ➝ $114.00
12/22/2022BTIG ResearchBoost TargetBuy$125.00 ➝ $160.00
12/16/2022UBS GroupUpgradeNeutral ➝ Buy$100.00 ➝ $158.00
12/13/2022Cantor FitzgeraldBoost Target$150.00 ➝ $174.00
11/3/2022Royal Bank of CanadaLower TargetOutperform$193.00 ➝ $190.00
11/3/2022The Goldman Sachs GroupBoost TargetBuy$152.00 ➝ $171.00
11/3/2022Credit Suisse GroupBoost TargetNeutral$93.00 ➝ $101.00
11/3/2022Robert W. BairdBoost Target$110.00 ➝ $152.00
11/3/2022Needham & Company LLCLower TargetBuy$162.00 ➝ $158.00
10/17/2022Leerink PartnersBoost TargetOutperform$126.00 ➝ $145.00
10/13/2022Morgan StanleyBoost TargetEqual Weight$135.00 ➝ $141.00
9/8/2022Morgan StanleyBoost TargetEqual Weight$100.00 ➝ $135.00
8/9/2022Royal Bank of CanadaBoost TargetOutperform$160.00 ➝ $182.00
8/3/2022Royal Bank of CanadaBoost TargetOutperform$156.00 ➝ $160.00
8/3/2022GuggenheimBoost Target$100.00 ➝ $122.00
8/3/2022Morgan StanleyBoost TargetEqual Weight$80.00 ➝ $100.00
8/3/2022Credit Suisse GroupBoost TargetNeutral$90.00 ➝ $93.00
8/3/2022BarclaysBoost Target$104.00 ➝ $125.00
8/3/2022OppenheimerBoost Target$125.00 ➝ $150.00
7/29/2022Needham & Company LLCBoost TargetBuy$150.00 ➝ $162.00
6/24/2022Cantor FitzgeraldLower TargetOverweight$140.00 ➝ $128.00
6/24/2022Credit Suisse GroupLower TargetNeutral$95.00 ➝ $90.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$181.00 ➝ $155.00
5/19/2022Morgan StanleyLower TargetEqual Weight$77.00 ➝ $74.00
4/12/2022Morgan StanleyLower TargetEqual Weight$80.00 ➝ $77.00
3/7/2022Morgan StanleyBoost TargetEqual Weight$71.00 ➝ $80.00
3/2/2022BarclaysLower Target$125.00 ➝ $104.00
3/2/2022Royal Bank of CanadaBoost TargetOutperform$145.00 ➝ $150.00
2/1/2022Morgan StanleyLower TargetEqual Weight$92.00 ➝ $71.00
1/18/2022Morgan StanleyBoost TargetEqual Weight$90.00 ➝ $92.00
1/11/2022Needham & Company LLCReiterated RatingBuy$150.00
1/5/2022Needham & Company LLCLower TargetBuy$157.00 ➝ $150.00
12/9/2021OppenheimerUpgradeMarket Perform ➝ Outperform$125.00
11/5/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$88.00 ➝ $130.00
11/4/2021Cantor FitzgeraldBoost TargetOverweight$128.00 ➝ $140.00
11/4/2021Royal Bank of CanadaLower TargetOutperform$148.00 ➝ $145.00
11/4/2021Needham & Company LLCLower TargetBuy$166.00 ➝ $157.00
10/15/2021Berenberg BankReiterated RatingHold$90.00
10/12/2021Credit Suisse GroupBoost TargetNeutral$75.00 ➝ $100.00
10/12/2021Leerink PartnersReiterated RatingBuy
10/12/2021Needham & Company LLCReiterated RatingBuy
10/12/2021BTIG ResearchBoost TargetBuy$110.00 ➝ $125.00
10/7/2021Robert W. BairdInitiated CoverageBuy$110.00
9/15/2021GuggenheimUpgradeNeutral ➝ Buy
8/16/2021Morgan StanleyLower TargetEqual Weight$93.00 ➝ $90.00
8/5/2021Credit Suisse GroupBoost TargetNeutral$72.00 ➝ $75.00
8/5/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$92.00 ➝ $87.00
7/1/2021Berenberg BankInitiated CoverageHold$85.00
6/14/2021BTIG ResearchInitiated CoverageBuy$110.00
5/3/2021Needham & Company LLCInitiated CoverageBuy$166.00
4/19/2021Morgan StanleyLower TargetEqual Weight$95.00 ➝ $93.00
4/16/2021William BlairReiterated RatingBuy
3/21/2021Leerink PartnersReiterated RatingBuy
3/2/2021Royal Bank of CanadaLower TargetOutperform$143.00 ➝ $132.00
3/2/2021Needham & Company LLCReiterated RatingBuy$166.00
3/2/2021Leerink PartnersBoost TargetOutperform$125.00 ➝ $126.00
3/2/2021Piper SandlerLower TargetNeutral$140.00 ➝ $130.00
2/26/2021MizuhoBoost TargetBuy$158.00 ➝ $160.00
1/12/2021Smith Barney CitigroupDowngradeBuy ➝ Neutral
1/11/2021UBS GroupDowngradeBuy ➝ Neutral
1/8/2021OppenheimerReiterated RatingHold ➝ Neutral
1/8/2021Credit Suisse GroupLower TargetNeutral$156.00 ➝ $73.00
1/8/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$96.00
1/8/2021Robert W. BairdLower TargetOutperform$223.00 ➝ $110.00
1/8/2021CowenLower TargetOutperform$213.00 ➝ $114.00
1/8/2021Needham & Company LLCLower TargetBuy$182.00 ➝ $166.00
1/8/2021BarclaysLower TargetPositive ➝ Overweight$192.00 ➝ $125.00
1/8/2021Cantor FitzgeraldLower TargetOverweight$217.00 ➝ $128.00
1/8/2021Royal Bank of CanadaLower TargetOutperform$200.00 ➝ $143.00
1/8/2021MizuhoLower TargetBuy$204.00 ➝ $158.00
1/8/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$182.00 ➝ $95.00
1/8/2021Raymond JamesDowngradeOutperform ➝ Market Perform
1/8/2021Leerink PartnersLower TargetOutperform$197.00 ➝ $125.00
1/4/2021Piper SandlerBoost TargetOverweight$200.00 ➝ $240.00
12/14/2020Smith Barney CitigroupBoost Target$190.00 ➝ $215.00
12/14/2020Credit Suisse GroupLower TargetNeutral$162.00 ➝ $156.00
12/8/2020MizuhoBoost TargetBuy$192.00 ➝ $204.00
11/11/2020Berenberg BankInitiated CoverageHold$140.00
11/6/2020Credit Suisse GroupLower TargetNeutral$167.00 ➝ $162.00
11/6/2020Leerink PartnersLower TargetOutperform$214.00 ➝ $197.00
10/28/2020UBS GroupInitiated CoverageBuy$212.00
10/11/2020Royal Bank of CanadaReiterated RatingBuy
9/15/2020CitigroupBoost TargetBuy$177.00 ➝ $190.00
8/31/2020HC WainwrightLower TargetBuy$260.00 ➝ $221.00
8/24/2020Raymond JamesInitiated CoverageOutperform$200.00
8/21/2020Bank of AmericaLower TargetBuy$190.00 ➝ $189.00
8/20/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$185.00 ➝ $167.00
8/10/2020Morgan StanleyBoost TargetOverweight$172.00 ➝ $182.00
8/4/2020Piper SandlerLower TargetOverweight$206.00 ➝ $200.00
8/3/2020Credit Suisse GroupReiterated RatingBuy
6/22/2020JPMorgan Chase & Co.Boost TargetOverweight$160.00 ➝ $190.00
6/16/2020HC WainwrightReiterated RatingBuy$260.00
6/10/2020Bank of AmericaReiterated RatingBuy$180.00
6/8/2020HC WainwrightReiterated RatingBuy$260.00
6/8/2020Robert W. BairdReiterated RatingBuy$192.00
5/17/2020NomuraReiterated RatingBuy$230.00
5/15/2020JPMorgan Chase & Co.Reiterated RatingBuy
5/15/2020Robert W. BairdReiterated RatingBuy$192.00
5/15/2020HC WainwrightReiterated RatingBuy$260.00
5/7/2020Needham & Company LLCInitiated CoverageBuy$182.00
5/7/2020Credit Suisse GroupReiterated RatingBuy$185.00
5/7/2020OppenheimerReiterated RatingHold
5/6/2020Royal Bank of CanadaReiterated RatingBuy$182.00
4/30/2020MizuhoReiterated RatingBuy$183.00
4/15/2020Morgan StanleyLower TargetOverweight$173.00 ➝ $172.00
3/30/2020MizuhoInitiated CoverageBuy$183.00
2/28/2020JPMorgan Chase & Co.Lower TargetOverweight$172.00 ➝ $160.00
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$211.00 ➝ $217.00
2/27/2020JMP SecuritiesLower TargetOutperform$280.00 ➝ $217.00
2/25/2020Nomura SecuritiesReiterated RatingBuy$230.00
1/23/2020Leerink PartnersReiterated RatingBuy$216.00
1/14/2020Credit Suisse GroupReiterated RatingBuy$185.00
1/14/2020CowenReiterated RatingBuy$213.00
1/7/2020Bank of AmericaReiterated RatingBuy$187.00
12/30/2019OppenheimerReiterated RatingHold
12/26/2019CitigroupReiterated RatingBuy$177.00
12/25/2019Nomura SecuritiesReiterated RatingBuy$230.00
12/24/2019The Goldman Sachs GroupReiterated RatingBuy$180.00
12/24/2019Morgan StanleyBoost TargetOverweight$160.00 ➝ $173.00
12/24/2019Credit Suisse GroupReiterated RatingOverweight ➝ Outperform$190.00 ➝ $185.00
12/23/2019Piper Sandler CompaniesReiterated RatingBuy$210.00
12/23/2019Royal Bank of CanadaLower TargetOutperform$215.00 ➝ $200.00
12/20/2019Robert W. BairdBoost TargetOutperform$181.00 ➝ $192.00
12/18/2019Nomura SecuritiesReiterated RatingBuy$230.00
12/17/2019CitigroupBoost TargetBuy$167.00 ➝ $177.00
12/15/2019CowenInitiated CoverageBuy$213.00
12/15/2019BarclaysReiterated RatingBuy$202.00
12/13/2019HC WainwrightBoost Target$160.00 ➝ $260.00
12/13/2019Cantor FitzgeraldBoost TargetOverweight$175.00 ➝ $211.00
12/13/2019Leerink PartnersReiterated RatingOutperform$186.00 ➝ $216.00
12/13/2019Piper Sandler CompaniesReiterated RatingBuy$185.00 ➝ $210.00
12/13/2019Credit Suisse GroupBoost TargetOutperform$185.00 ➝ $190.00
12/13/2019Janney Montgomery ScottBoost TargetBuy$160.00 ➝ $175.00
12/13/2019Royal Bank of CanadaReiterated RatingOutperform$215.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.79 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 27 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 29 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 18 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 22 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
8/22/2024
  • 29 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 19 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 23 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 23 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Sarepta Therapeutics logo
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $110.86
Low: $108.72
High: $111.38

50 Day Range

MA: $122.50
Low: $104.54
High: $132.02

52 Week Range

Now: $110.86
Low: $78.67
High: $173.25

Volume

1,195,494 shs

Average Volume

1,233,821 shs

Market Capitalization

$10.59 billion

P/E Ratio

88.69

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Sarepta Therapeutics?

The following sell-side analysts have issued stock ratings on Sarepta Therapeutics in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, StockNews.com, TheStreet, UBS Group AG, Wedbush, and William Blair.
View the latest analyst ratings for SRPT.

What is the current price target for Sarepta Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Sarepta Therapeutics in the last year. Their average twelve-month price target is $181.33, suggesting a possible upside of 63.6%. Leerink Partners has the highest price target set, predicting SRPT will reach $230.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $109.00 for Sarepta Therapeutics in the next year.
View the latest price targets for SRPT.

What is the current consensus analyst rating for Sarepta Therapeutics?

Sarepta Therapeutics currently has 1 hold rating, 20 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRPT will outperform the market and that investors should add to their positions of Sarepta Therapeutics.
View the latest ratings for SRPT.

What other companies compete with Sarepta Therapeutics?

Other companies that are similar to Sarepta Therapeutics include Jazz Pharmaceuticals, Ionis Pharmaceuticals, Mirati Therapeutics, ACADIA Pharmaceuticals and Wave Life Sciences. Learn More about companies similar to Sarepta Therapeutics.

How do I contact Sarepta Therapeutics' investor relations team?

Sarepta Therapeutics' physical mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (617) 274-4000 and its investor relations email address is [email protected]. The official website for Sarepta Therapeutics is www.sareptatherapeutics.com. Learn More about contacing Sarepta Therapeutics investor relations.